

論文全著者名. 論題. 雑誌名. 発行年; 巻 :始頁-終頁	著者名
Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). Clin Lung Cancer. 2020 Nov;21(6):e592-e596. doi: 10.1016/j.clcc.2020.05.011. Epub 2020 May 21. PMID: 32611505	Miura S, Yamanaka T, Kato T, Ikeda S, Horinouchi H, Ichihara E, <u>Kanazu M</u> , Takiguchi Y, Tanaka K, Goto Y, Sata M, Hagiwara K, Okamoto H, Tanaka H
Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation. Future Oncol. 2020 Jul;16(21):1537-1547. doi: 10.2217/fo-2020-0203. Epub 2020 Jul 14.	Imamura F, Kimura M, <u>Yano Y</u> , <u>Mori M</u> , Suzuki H, Hirashima T, Ihara S, Komuta K, Shiroyama T, Nagatomo I, Kumagai T
Radiographic change over 11 years in a patient with asbestos-related pleural disease. Respirol Case Rep. 2020 Aug 19;8(7):e00642. doi: 10.1002/rcr2.642. eCollection 2020 Oct.	Hara R, Yano Y, Okabe F, Kuge T, Mori M, Urasaki K
Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study. Thorac Cancer. 2020 Nov;11(11):3317-3325. doi: 10.1111/1759-7714.13675. Epub 2020 Sep 28.	Yamamoto Y, Yano Y, Kuge T, Okabe F, Ishijima M, Uenami T, Kanazu M, Akazawa Y, Yamaguchi T, Mori M
Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study. Thorac Cancer. 2021 Jan;12(1):90-96. doi: 10.1111/1759-7714.13718. Epub 2020 Oct 29.	<u>Kanazu M</u> , <u>Mori M</u> , Kimura M, Nishino K, Shiroyama T, Nagatomo I, Ihara S, Komuta K, Suzuki H, Hirashima T, Kumagai T, Imamura F
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study. Invest New Drugs. 2021 Jan 6. doi: 10.1007/s10637-020-01060-8. Online ahead of print.	Sugimoto T, Fujimoto D, Sato Y, Tamiya M, Yokoi T, Tamiya A, Iwasawa S, Hata A, Uchida J, Fukuda Y, Hara S, <u>Kanazu M</u> , Hirano K, Kokubo M, Yamamoto N

<p>Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. <i>Eur J Cancer</i> 2021 Jan 21;145:183–193. doi: 10.1016/j.ejca.2020.12.026. Online ahead of print.</p>	<p>Ito K, Yamanaka T, Hayashi H, Hattori Y, Nishino K, Kobayashi H, Oya Y, Yokoyama T, Seto T, Azuma K, Fukui T, Kozuki T, Nakamura A, Tanaka K, Hirano K, Yokoi T, Daga H, Sakata S, Fujimoto D, <u>Mori M</u>, Maeno K, Aoki T, Tamura A, Miura S, Watanabe S, Akamatsu H, Hataji O, Suzuki K, Hontsu S, Azuma K, Bessho A, Kubo A, Okuno M, Nakagawa K, Yamamoto N</p>
<p>A phase II study of first-line afatinib for patients aged <math>\geq 75</math> years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. <i>BMC Cancer</i>. 2021 Mar 1;21(1):208. doi: 10.1186/s12885-021-07861-1.</p>	<p>Minegishi Y, Yamaguchi O, Sugawara S, Kuyama S, Watanabe S, Usui K, <u>Mori M</u>, Hataji O, Nukiwa T, Morita S, Kobayashi K, Gemma A</p>
<p>EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib. <i>Thorac Cancer</i>. 2021;12:1441–1444.</p>	<p>Hara R, Kanazu M, Iwai A, Kuge T, Ishijima M, Uenami T, Akazawa Y, Yano Y, Yamaguchi T, Mori M</p>
<p>Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report. <i>Thorac Cancer</i>. 2021;12:1935–1939.</p>	<p>Kuge T, Okabe F, Yamamoto Y, Ishijima M, Uenami T, Kanazu M, Akazawa Y, Yano Y, Yamaguchi T, Mori M</p>

<p>Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study BMC Cancer (2021) 21:346  <a href="https://doi.org/10.1186/s12885-021-08048-4">https://doi.org/10.1186/s12885-021-08048-4</a></p>	<p>Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, Yokoyama T, Ishida T, Matsumoto H, Hirano K, Kominami R, Tomii K, Suzuki H, Hirashima T, Tanaka S, Uchida J, Morita M, <u>Kanazu M</u>, <u>Mori M</u>, Nagata K, Fukuda I, Tamiya M</p>
<p>Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Mar 18. doi: 10.1001/jamaoncol.2021.0113. Online ahead of print. PMID: 33734289</p>	<p>Zenke Y, Tsuboi M, Chiba Y, Tsujino K, Satouchi M, Sawa K, Shimizu J, Daga H, Fujimoto D, <u>Mori M</u>, Aoki T, Sawa T, Omori S, Saka H, Iwamoto Y, Okuno M, Hirashima T, Kashiwabara K, Tachihara M, Ymamoto N, Nakagawa K</p>
<p>肺がんゲノム医療の進歩と問題点. 豊中市医師会月報 2020年7月 メディカル・トピックス</p>	<p>森 雅秀</p>
<p>非小細胞肺癌に対する分子標的薬開発の現状と展望. 2020年8月 癌と化学療法</p>	<p>金津 正樹</p>